Genes Associated with Disease-Free Survival Prognosis of Renal Cancers
Renal Cell Carcinoma (RCC) incidence has consistently been on the rise in recent years. There are 4 main types of RCC, namely Bladder Urothelial Carcinoma (BLCA), Kidney Chromophobe (KICH), Kidney Renal Clear Cell Carcinoma (KIRC), and Kidney Renal Papillary Cell Carcinoma (KIRP). The aim of this investigation is to identify genes in the tumors across the various renal cancers that can best distinguish patients with good versus those with poor disease-free survival (DFS), and determine pertinent cancer-related pathways that genes associated with DFS reside in. We hypothesized that genes significantly associated with DFS are associated with pathways that can be targeted for gene therapy and be identified as potential biomarkers for RCC. Genes in the tumors of RCC patients significantly associated with DFS were identified from The Cancer Genome Atlas (TCGA) database using Kaplan-Meier analyses. Genes with high expression that are associated with poor survival of patients might serve as potential biomarkers and/or targets for gene therapy across renal associated cancers with the exception of BLCA.
KeywordsRenal Cell Carcinoma (RCC) Bladder Urothelial Carcinoma (BLCA) Kidney Chromophobe (KICH) Kidney Renal Clear Cell Carcinoma (KIRC) Kidney Renal Papillary Cell Carcinoma (KIRP) Gene therapy Biomarkers Disease-free survival Prognosis
The authors thank their mentors, A/P Caroline Lee Guat Lay and Mr. Lee Wai Yeow for their constant guidance and support.
- 2.World Cancer Research Fund International. Kidney cancer statistics. Retrieved from http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/kidney-cancer-statistics.
- 3.World Health Organisation. (2017). Obesity and overweight. Retrieved from http://www.who.int/mediacentre/factsheets/fs311/en/.
- 8.Chakraborty, R., Rao, C. R., & Sen, P. K. (2012). Bioinformatics in human health and heredity (Vol. 28). Newnes Books.Google Scholar
- 15.Vailaya, A., et al. (2004). An architecture for biological information extraction and representation. Bioinformatics, 21(4), 430–438. https://doi.org/10.1093/bioinformatics/bti187.
- 16.King, J. Y., et al. (2005). Pathway analysis of coronary atherosclerosis. Physiological Genomics, 23(1), 103–118. https://doi.org/10.1152/physiolgenomics.00101.2005.CrossRefPubMedGoogle Scholar
- 17.Ashley, E. A., et al. (2006). Network analysis of human in-stent restenosis. Circulation, 114(24), 2644–2654. https://doi.org/10.1161/circulationaha.106.637025.
- 18.World-Health-Organisation. (2001). Biomarkers in risk assessment: Validity and validation. Retrieved from http://www.inchem.org/documents/ehc/ehc/ehc222.htm.
- 20.Lin, K., Lipsitz, R., Miller, T., & Janakiraman, S. (2008). Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 149(3), 192–199.Google Scholar
- 24.Flemming, A. (2015). Cancer stem cells: Targeting the root of cancer relapse. Nature Reviews Drug Discovery, 14(165). https://doi.org/10.1038/nrd4560.
- 25.Jen, J., & Wang, Y.-C. (2016). Zinc finger proteins in cancer progression. Journal of Biomedical Science, 23(53). https://doi.org/10.1186/s12929-016-0269-9.